SOPRANO - Stereotactic radiotherapy alone or stereotactic radiotherapy follow by niraparib treatment for ovarian cancer with progressive disease in three or less lesions, or recurrence of 3 or less metastatic lesions that had previously achieved complete response.

This trial is for women aged 18 and over who have been diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer. To be considered, your cancer must have started growing again in no more than three distinct spots, with each spot measuring less than 4 centimetres across.

You must have previously taken a PARP inhibitor medicine for at least six months, and this must have been your most recent cancer treatment. You also need to be generally well enough to manage daily activities, have satisfactory blood and organ test results, and not have plans to undergo surgery for this cancer recurrence.

You will not be eligible if you are pregnant, if your cancer has spread to more than three areas, or if your tumours cannot be safely targeted with SBRT radiotherapy. Your hospital cancer team will review your scans and medical history to confirm whether this trial is suitable for you.

If you take part, you will receive SBRT radiotherapy delivered over three to eight short outpatient visits across one to three weeks. Depending on which group you join, you may also take a daily capsule of niraparib at home for as long as it continues to work. During the first year, you will visit the clinic every eight weeks for blood tests, health checks, and imaging scans (such as CT, MRI, or PET-CT) to see how well the treatment is working. In the second year onwards, these visits will reduce to every 12 weeks. Your GP will be kept updated throughout. You will remain on the trial until your cancer shows signs of growth, you experience troublesome side effects, or you choose to leave.